Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1100-1109

  Wei, Guo Xian ^a   Campagna, Alexander N ^a   Bobek, Libuse A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antimicrobial peptides; CBD; Mucins; Saliva; Susceptibility

Indexed keywords

CHLORHEXIDINE; CRYSTAL VIOLET; DYE; MAGAININ 2; MUCIN 7; PEPTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; MAGAININ 2 PEPTIDE, XENOPUS; MUC7 PROTEIN, HUMAN; MUCIN; OXAZINE DERIVATIVE; PEPTIDE; RESAZURIN; XANTHENE DERIVATIVE; XENOPUS PROTEIN;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; BIOFILM; CONTROLLED STUDY; DILUTION; ESCHERICHIA COLI; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS GINGIVALIS; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS GORDONII; STREPTOCOCCUS MUTANS; BACTERIAL COUNT; BIOMASS; COMPARATIVE STUDY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGICAL EXAMINATION; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; BIOMASS; COLONY COUNT, MICROBIAL; GENTIAN VIOLET; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MUCINS; OXAZINES; PEPTIDES; STREPTOCOCCUS MUTANS; XANTHENES; XENOPUS PROTEINS;

EID: 33749170651     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl120     Document Type: Article

References (34)

1. Hancock RE, Lehrer R. Cationic peptides: A new source of antibiotics. Trends Biotechnol 1998; 16: 82-8.
2. Edgerton M, Koshlukova SE, Lo TE et al. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 1998; 273: 20438-47.
3. Nibbering PH, Danesi R, van't Wout JW et al. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin Investig Drugs 2002; 11: 309-18.
4. Edgerton M, Koshlukova SE, Araujo MW et al. Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. Antimicrob Agents Chemother 2000; 44: 3310-6.
5. Gyurko C, Lendenmann U, Troxler RF et al. Candida albicans mutants deficient in respiration are resistant to the small cationic salivary antimicrobial peptide histatin 5. Antimicrob Agents Chemother 2000; 44: 348-54.
6. Ruissen AL, Groenink J, Krijtenberg P et al. Internalisation and degradation of histatin 5 by Candida albicans. Biol Chem 2003; 384: 183-90.
7. Sajjan US, Tran LT, Sole N et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 2001; 45: 3437-44.
8. MacKay BJ, Denepitiya L, Iacono VJ et al. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-richpolypeptides on Streptococcus mutans. Infect Immun 1984; 44: 695-701.
9. Payne JB, Iacono VJ, Crawford IT et al. Selective effects of histidine-rich polypeptides on the aggregation and viability of Streptococcus mutans and Streptococcus sanguis. Oral Microbiol Immunol 1991; 6: 169-76.
10. Murakami Y, Nagata H, Amano A et al. Inhibitory effects of human salivary histatins and lysozyme on coaggregation between Porphyromonas gingivalis and Streptococcus mitis. Infect Immun 1991; 59: 3284-6.
11. Murakami Y, Xu T, Helmerhorst EJ et al. Inhibitory effect of synthetic histatin 5 on leukotoxin fturn Actinobacillus actinomycetem-comitans. Oral Microbiol Immunol 2002; 17: 143-9.
12. Helmerhorst EJ, Breeuwer P, van't Hof W et al. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem 1999; 274: 7286-91.
13. Tabak LA. In defense of the oral cavity: Structure, biosynthesis, and function of salivary mucins. Annu Rev Physiol 1995; 57: 547-64.
14. Bobek LA. Situ H. MUC7 20-Mer: Investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob Agents Chemother 2003; 47: 643-52.
15. Satyanarayana J, Situ H, Narasimhamurthy S et al. Divergent solid-phase synthesis and candidacidal activity of MUC7 D1, a 51-residue histidine-rich N-terminal domain of human salivary mucin MUC7. J Pept Res 2000; 56: 275-82.
16. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 2000; 44: 1485-93.
17. Situ H, Wei G, Smith CJ et al. Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity. Biochem J 2003; 375: 175-82.
18. Wei GX, Bobek LA. In vitro synergic. antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. J Antimicrob Chemother 2004; 53: 750-8.
19. Wei GX, Bobek LA. Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: Antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells. Antimicrob Agents Chemother 2005; 49: 2336-42.
20. Rothstein DM, Helmerhorst EJ, Spacciapoli P etal. Histatin-derived peptides: Potential agents to treat localised infections. Expert Opin Emerg Drugs 2002; 7: 47-59.
21. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Tentative Standard M26-T NCCLS, Wayne, PA, USA, 1992.
22. Ceri H, Olson ME, Stremick C et al. The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
23. Banas JA. Virulence properties of Streptococcus mutans. Front Biosci 2004; 9: 1267-77.
24. Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. Oral Dis 2003; 9: 23-9.
25. Nishimura E, Eto A, Kato M et al. Oral streptococci exhibit diverse susceptibility to human beta-defensin-2: Antimicrobial effects of hBD-2 on oral streptococci. Curr Microbiol 2004; 48: 85-7.
26. Mineshiba F, Takashiba S, Mineshiba J et al. Antibacterial activity of synthetic human B defensin-2 against periodontal bacteria. J Int Acad Periodontol 2003; 5: 35-40.
27. Kim SS, Kim S, Kim E et al. Synergistic inhibitory effect of cationic peptides and antimicrobial agents on the growth of oral streptococci. Caries Res 2003; 37: 425-30.
28. Ouhara K, Komatsuzawa H, Yamada S et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-96.
29. Helmerhorst EJ, Hodgson R, van't Hof W et al. The effects of histatin-derived basic antimicrobial peptides on oral biofilms. J Dent Res 1999; 78: 1245-50.
30. Brogden KA. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
31. Liu B, Rayment S, Oppenheim FG et al. Isolation of human salivary mucin MG2 by a novel method and characterization of its interactions with oral bacteria, Arch Biochem Biophys 1999; 364: 286-93.
32. Liu B, Rayment SA, Gyurko C et al. The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity. Biochem J 2000; 345: 557-64.
33. Scares RV, Liu B, Oppenheim FG et al. Structural characterisation of cysteines in a bacterial-binding motif of human salivary mucin MG2. Arch Oral Biol 2002; 47: 591-7.
34. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J Med Microbiol 1996; 44: 79-87.